🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed CLL

A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites📍 Tübingen📍 Tübingen University Hospital Tuebingen · Tests: CAR-T cells targeting CD19 and CD22 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site📍 Ann Arbor University of Michigan Rogel Cancer Center · Tests: Biospecimen Collection, Pomalidomide Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. NCT06542250Phase 1, Phase 231 sites📍 La Jolla📍 Boston📍 Rochester AstraZeneca · Tests: AZD5492 A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL NCT07609823Phase 21 site📍 Nanjing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma NCT06839053Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Gastrointestinal Endoscopy, Rituximab Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) NCT07221500Phase 240 sites📍 Phoenix📍 Duarte📍 Los Angeles Nurix Therapeutics, Inc. · Tests: NX-5948 Allogeneic CARCIK-CD19 in Adults/Pediatric B-cell NHL or Chronic Lymphocytic Leukemia NCT05869279Phase 1, Phase 21 site📍 Bergamo Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Tests: CARCIK-CD19 Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) NCT06644183Phase 1, Phase 21 site📍 Boston Jennifer R. Brown, MD, PhD · Tests: Roginolisib, Venetoclax, Rituximab CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ NCT06355739NA2 sites📍 Tianjin📍 Tianjin Zhu Xiaofan · Tests: CAR T cell injection A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia NCT07061951Phase 29 sites📍 Duarte📍 Irvine📍 Sacramento National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Mirdametinib Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites📍 Heidelberg📍 Heidelberg University Hospital Heidelberg · Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) NCT05010564Phase 11 site📍 Houston Baylor College of Medicine · Tests: Autologous TRICAR-ALL T-cells and lymphodepletion chemotherapy Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL NCT05147467Phase 211 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG2575 Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) NCT06533579Phase 1, Phase 211 sites📍 Duarte📍 Los Angeles📍 Denver Vironexis Biotherapeutics Inc. · Tests: Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101, Dose Level 4, VNX-101 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia NCT05091424Phase 131 sites📍 Rochester📍 New York📍 Columbus Hoffmann-La Roche · Tests: Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL NCT04494503Phase 1, Phase 218 sites📍 Beijing📍 Chongqing📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-2575, Rituximab, Ibrutinib B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies NCT06191887Phase 11 site📍 Jacksonville Mayo Clinic · Tests: Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites📍 Beijing📍 Beijing📍 Shanghai Medolution Ltd. · Tests: Keynatinib CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies NCT04892277Phase 11 site📍 Rochester Mayo Clinic · Tests: Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563, Bendamustine, Biospecimen Collection, Bone Marrow Aspirati… Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) NCT03666000Phase 115 sites📍 Tampa📍 Atlanta📍 Atlanta Imugene Limited · Tests: Azer-cel, Fludarabine, Cyclophosphamide, IL-2, Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma NCT06916767Phase 11 site📍 Cleveland Paolo Caimi, MD · Tests: BAFF CAR-T, Obinutuzumab, Cyclophosphamide, Fludarabine A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia NCT07205315EARLY Phase 12 sites📍 Zhengzhou📍 Tianjin Grit Biotechnology · Tests: GT801 Injection A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088Phase 12 sites📍 Columbus📍 Columbus Sumithira Vasu · Tests: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial NCT04941716Phase 21 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Acalabrutinib, Venetoclax, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy